PANP25: Viable Strategies for Using JAK Inhibitors in Vitiligo: An Online Activity

PANP25: Viable Strategies for Using JAK Inhibitors in Vitiligo: An Online Activity

This Seminar in Depth from the 2025 Fall Clinical Dermatology Conference for PAs and NPs explores the latest clinical data on the use of Janus kinase (JAK) inhibitors in vitiligo and features practical insights for incorporating JAK inhibitors into management plans for patients with vitiligo.

“This is the point I try to make to patients. I let them know it’s going to take time, even if you start to repigment. We’re excited about repigmentation, but you are not, because you still don’t look the way you want to look- you have speckled areas, et cetera, but it’s because the [melanin] factories are shut down. And when you start to wake them up again, you have to rebuild everything and it’s going to take some time.” - Dr. James Del Rosso

This activity is supported by an educational grant from Incyte.